QIAGEN introduces QIAsymphony sample processing option to GeneReader NGS workflow for non U.S. customers
QIAsymphony SP front-end adds higher sample throughput and additional flexibility to GeneReader NGS System
Hilden, Germany, October 5, 2016 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch outside of the United States of its QIAsymphony SP instrument as a front-end option for sample processing for the GeneReader NGS System*, adding highly automated, higher throughput sample volumes and high flexibility to the world’s first complete Sample to Insight solution for next-generation sequencing (NGS). The GeneReader NGS workflow can now integrate seamlessly with QIAsymphony SP, enabling laboratories outside the United States to perform sample processing of different sample types simultaneously with continuous loading, random access and greater speed for demanding environments.
“Where available, the GeneReader NGS System is gaining adoption as a complete, user-friendly solution for next-generation sequencing, and QIAsymphony SP adds a reliable front-end to the GeneReader NGS System for higher throughput workflows. We are currently marketing the GeneReader NGS workflow outside the United States. As an alternative to the QIAcube, which automates lower throughput sample processing, QIAsymphony SP handles varying sample volumes and types simply and efficiently for GeneReader NGS users,” said Jonathan Arnold, QIAGEN’s Oncology Franchise Business Leader.
QIAsymphony SP delivers efficient processing with continuous loading of up to 96 samples and dozens of gold standard, proven protocols to process and purify samples for analysis. QIAsymphony SP is registered with the FDA and part of FDA approved workflows. It also offers cutting-edge process control and integrates with Laboratory Information Management Systems (LIMS). QIAsymphony SP is available now for processing tissue samples for the GeneReader NGS System and its market leading liquid biopsy sample processing solutions will be available for GeneReader in early 2017. In lower-throughput settings, the QIAcube automates sample processing of up to 12 spin columns at a time, offering maximum versatility for specialized needs.
QIAGEN introduced the GeneReader NGS workflow in November 2015 and is developing a range of enhancements that deliver further value for non-U.S. customers. Earlier this year, an extensive quality control package with verification data was added to reinforce the proven accuracy of GeneReader NGS and to facilitate system setup, quality assurance and training for labs. The GeneRead Actionable Insights Tumor Panel, for detection of mutations in 12 genes implicated in several of the most prevalent cancers, was optimized to provide the industry’s first Sample to Insight NGS solution for analyzing both non-invasive liquid biopsies and FFPE tissue samples. QIAGEN currently is developing specialized panels to run on the GeneReader NGS outside the United States to address unmet clinical research needs in lung and breast cancers.
For more information on the QIAsymphony SP sample prep module please visit www.qiagen.com.
*GeneReader NGS System is currently only available for sale outside the United States
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of June 30, 2016, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).